Table 2:

Sample description of the SUCCESS-A study variables considered by the PRIM algorithm, including the BRCA1-defined cluster id. Patients were randomized to either standard of care (arm AB) or standard of care plus Gemcitabine (arm AA).

Variable	Treatment
	AA (n = 1590)	AB (n = 1624)	P-value
ER status			0.411
Positive	1086 (0.68)	1132 (0.70)
Negative	504 (0.32)	492 (0.30)
HER2 status			0.188
Positive	509 (0.32)	484 (0.30)
Negative	1081 (0.68)	1140 (0.70)
PR status			0.456
Positive	1003 (0.63)	1046 (0.64)
Negative	587 (0.37)	578 (0.36)
MenoDause status			0.334
Premenopausal	667 (0.42)	653 (0.40)
Postmenopausal	923 (0.58)	971 (0.60)
Grade			0.451
G1 (well differentiated)	81 (0.05)	68 (0.04)
G2 (moderately differentiated)	763 (0.48)	778 (0.48)
G3 (poorly differentiated)	746 (0.47)	778 (0.48)
T stage			0.823
pT0	1 (0.00)	0 (0.00)
pT1	657 (0.41)	672 (0.41)
PT2	830 (0.52)	838 (0.52)
pT3	81 (0.05)	90 (0.06)
pT4	21 (0.01)	24 (0.01)
N stage			0.487
pN0	570 (0.36)	561 (0.35)
pN1	697 (0.44)	747 (0.46)
pN2	229 (0.14)	213 (0.13)
pN3	94 (0.06)	103 (0.06)
Tumor type			0.899
Invasive ductal	1252 (0.79)	1278 (0.79)
Invasive lobular	165 (0.10)	175 (0.11)
Other invasive epithelial breast cancer	173 (0.11)	171 (0.11)
Age categorized			0.583
(−Inf,50]	654 (0.41)	639 (0.39)
(50,65]	693 (0.44)	727 (0.45)
(65, Inf]	243 (0.15)	258 (0.16)
BMI categorized			0.387
(−Inf,25]	739 (0.46)	771 (0.47)
(25,30]	537 (0.34)	513 (0.32)
(30, Inf]	314 (0.20)	340 (0.21)
CLUSTER ID			0.538
1	144 (0.09)	159 (0.10)
2	150 (0.09)	123 (0.08)
3	353 (0.22)	345 (0.21)
4	139 (0.09)	142 (0.09)
5	156 (0.10)	185 (0.11)
6	169 (0.11)	161 (0.10)
7	254 (0.16)	265 (0.16)
8	155 (0.10)	172 (0.11)
9	70 (0.04)	72 (0.04)